Skip to content

Board of directors bios

Christopher Posner

Chief Executive Officer, President, and Director

Mr. Posner has broad experience in commercial and marketing operations and product management at both large and specialty pharmaceutical companies, where he has focused on products for autoimmune, inflammatory and pain conditions, including Xeljanz® and Enbrel®. Since July 2017, he has been the Chief Executive Officer of LEO Pharma, Inc. US, a subsidiary of LEO Pharma A/S, a global healthcare company specializing in dermatology and critical care, including such conditions as psoriasis and atopic dermatitis. Prior to joining LEO, he was the Head of Worldwide Commercial Operations at R-Pharma-US, LLC, a specialty pharmaceutical company focused on oncology and chronic immune disorders, from 2014 until 2017. Previously, Mr. Posner held a variety of senior management positions in commercial and marketing operations at Bristol-Myers Squibb Company, Pfizer Inc., Wyeth Pharmaceuticals, Inc. and Endo Pharmaceuticals plc. Mr. Posner holds an M.B.A. from Fuqua School of Business, Duke University and a B.A. in Economics from Villanova University.

Harrison M. Bains


Mr. Bains is a Director and current Chair of Mercer Funds, Inc., a registered investment company. He has served in multiple roles at Bristol Myers Squibb Company, including Vice President, Treasurer and acting Chief Financial Officer, from 1988 through his retirement in 2004. Mr. Bains’s career also includes serving as Senior Vice President of the Primary Industries group at Chase Manhattan Bank, Director of BG Medicine, Inc., Director of Bank of America Funds and 11 years with RJR Nabisco and two of its predecessor companies as Senior Vice President and Treasurer. He has served as a member of the board of trustees of the Park Avenue Armory since October 2007 and the Civil War Trust since September 2007, and previously served as a member of the board of trustees of the University of Redlands from October 1989 to May 2013. Mr. Bains earned an M.B.A. from the University of California, Berkeley and a B.A. in economics from the University of Redlands. He also completed the Advanced Management Program at Harvard Business School.

Jeffrey L. Ives, Ph.D.


Dr. Ives currently is a Venture Partner at New Leaf Venture Partners and a Principal at NeuroPharma Advisors, LLC. From 2008 until 2013, he served as the Chief Executive Officer of Satori Pharmaceuticals, Inc., a neurodegenerative disease company focused on discovery and development of breakthrough therapies for the treatment and prevention of Alzheimer’s disease. Prior to Satori, Dr. Ives led the CNS, pain and oncology research teams at Pfizer for over two decades and, from 2001-2007, served as a Senior Vice President leading the global Pharmacokinetics, Dynamics and Metabolism organization. Dr. Ives received his doctorate and master degrees from Yale University and received his bachelor of arts degree from Colgate University.

Susan Shiff, Ph.D.


Dr. Shiff currently serves as Senior Vice President and Head of the Center for Observational and Real-World Evidence (CORE) at Merck, known as MSD outside the United States and Canada. Dr. Shiff has over 20 years of experience in the pharmaceutical industry as leader in the development and implementation of evidence, access, and pricing strategies for products globally. Before joining Merck in 2014, she was Vice President of Global Health Economics, Data Sciences and Evidence-Based Medicine at Teva Pharmaceuticals. Prior to that, Dr. Shiff was Vice President of Evidence-Based Medicine and Market Access in Global Primary Care as well as Vice President of HEOR and Epidemiology in Emerging Markets at Pfizer.

She has also held senior positions at Roche and Johnson & Johnson. Dr. Shiff began her career at the Centers for Disease Control and Prevention. She holds an M.B.A. from Cornell University and a Ph.D. from the University of California at Los Angeles. Dr. Shiff currently serves on the Boards of Synthace Limited and the Merck Global Health Innovation Fund. In 2016, she was selected as one of FiercePharma’s Top 15 Women in Biopharma, in 2017 Proclinical named her as one of today’s most inspiring women in the pharmaceutical industry, and in 2018 CB Insights named CORE as one of the most innovative corporate labs in healthcare.

Martin Vogelbaum


Martin Vogelbaum is currently a Partner at Rho Ventures. He has more than 24 years of private and public deal transaction and investment experience in the life sciences as both a senior business development executive and venture capitalist. Mr. Vogelbaum joined Rho as a Partner in 2005 and primarily focuses on investments in biotechnology. Some representative investments include Cara (CARA), Gloucester Pharmaceuticals (sold to Celgene), SARcode Biosciences (sold to Shire), AqueSys (sold to Allergan) and Mersana Therapeutics (MRSN). From 2015-2017, Mr. Vogelbaum served as a Corporate Vice President, Business Development at Celgene Corporation (CELG) where he completed over $1.5B in product licensing and M&A transactions with private and public companies. 

Prior to Rho, he was a General Partner at Apple Tree Partners, a life sciences venture firm focused on early-stage companies and a General Partner at Oxford Bioscience Partners. Mr. Vogelbaum was a research associate in the bone marrow transplantation unit at Memorial-Sloan Kettering Hospital, where he conducted research in graft-versus-host-disease (GVHD). He received an A.B. in biology and history from Columbia University.

He currently serves on the Healthcare Advisory Board for the Partnership Fund for New York City as well as the Scientific Advisory Committee for Weill Cornell Medical College’s Daedalus Fund for Innovation.